The Irvine, CA-based company said at two years, about 80% of patients in the ARTISAN-SNM study achieved greater than or equal to 75% improvement, with 37% being completely dry.

Edwards Lifesciences management acknowledged some recently cancelled cases due to COVID-19 resurgence, but still offers confident outlook for the back half of the year.

The Abbott Park, IL-based company said the approval allows patients living with neurological conditions the ability to manage therapy directly from their personal smartphone.

This month marks the 20th anniversary of FDA clearing the da Vinci surgical robotics system for laparoscopic procedures.

The Marlborough, MA-based company said it will have a limited launch of the Watchman FLX Left Atrial Appendage Closure (LAAC) technology and a broader launch in 4Q20.

The Santa Clara, CA-based company said the AMBULATE Same-Day Discharge will enroll 150 patients in up to 10 centers to evaluate the VASCADE MVP Venous Vascular Closure System.

When Quest jumped onto the COVID-19 detection scene in early March the Centers for Disease Control and Prevention reported there were about 129 confirmed COVID-19 cases and at least 11 deaths.

Abbott's second-quarter earnings showed a mixed bag with pandemic disruptions on the medical device side of the business, and sales of COVID-19 tests driving growth for the diagnostic side.